Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference23 articles.
1. US Department of Health and Human Services. Adequate and well-controlled studies. 21 CFR §314.126 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.126.
2. Gassman AL, Nguyen CP, Joffe HV. FDA regulation of prescription drugs. N Engl J Med. 2017;376(7):674–82.
3. Smith MY, Benattia I, Strauss C, Bloss L, Jiang Q. Structured benefit-risk assessment across the product lifecycle: practical considerations. Ther Innov Regul Sci. 2017;51(4):501–8.
4. Wang J, Wolka A, Bullok K, Anglin G, Radawski C, Noel R. Implementation of structured benefit–risk assessments in marketing authorization applications: lessons learned. Ther Innov Regul Sci. 2016;50(6):718–23.
5. Juhaeri J. Benefit-risk evaluation: the past, present and future. Ther Adv Drug Saf. 2019;10:2042098619871180.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献